The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Vicuron Pharmaceuticals
• Treatments: Anidulafungin; Echinocandins; Fluconazole

Criteria

• Diagnosis of candidemia and/or other forms of invasive candidiasis.

• Should not have received greater than 48 hours of systemic antifungal therapy.

• Life expectancy should be greater than 72 hours.

• Should not have received greater than one week of prophylactic azole therapy 30 days prior to enrollment